Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus Price Target from Analysts

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have received a consensus rating of "Buy" from eight research firms that follow the company, according to MarketBeat. All eight equity research analysts have issued buy recommendations for the stock, and analysts have set an average twelve-month price target of $81.29 based on updates over the past year.

In recent days, several brokerage firms have commented on GPCR. JMP Securities reiterated a "market outperform" rating and set a price target of $91.00 in a report published on December 18th. Meanwhile, William Blair initiated coverage on Structure Therapeutics on February 28th, designating it an "outperform" investment. HC Wainwright also maintained a "buy" rating and set a target price of $80.00 in a report dated December 19th. Lastly, Stifel Nicolaus initiated coverage on January 8th, giving Structure Therapeutics a "buy" rating with a target price of $50.00.

Institutional Investors Pursue Structure Therapeutics

Recently, various institutional investors have adjusted their holdings in Structure Therapeutics. ANTIPODES PARTNERS Ltd increased its position in the company by 115.0% during the 4th quarter, now owning 1,034 shares valued at approximately $28,000 after acquiring an additional 553 shares. GAMMA Investing LLC saw significant growth in its holdings by 4,155.6% during the same quarter, owning 1,149 shares valued at around $31,000 after a purchase of 1,122 shares. Additionally, GF Fund Management CO. LTD. entered into a new position in Structure Therapeutics, investing around $34,000, while FNY Investment Advisers LLC bought a fresh stake worth about $40,000. Assetmark Inc. also expanded its investment by 120.0% in the 3rd quarter, now holding 1,318 shares valued at $58,000 after acquiring an additional 719 shares. It’s worth noting that institutional investors hold 91.78% of the company's stock.

Current Performance of Structure Therapeutics

On the last trading day, shares of Structure Therapeutics opened at $22.49. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -30.39, and a beta of -2.75. Over the past year, the stock reached a low of $19.61 and a high of $62.74. The 50-day moving average price sits at $26.34, while the 200-day moving average is $33.37.

Structure Therapeutics reported its quarterly earnings on February 27th, where it announced a loss of ($0.22) per share for the quarter. This result slightly exceeded the consensus estimate of a loss of ($0.23) by $0.01. Analysts predict that the company will report earnings of -0.82 per share for the current year.

Overview of Structure Therapeutics Inc.

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing innovative oral therapies to address various chronic diseases that lack effective treatments. Their leading candidate is GSBR-1290, an oral small molecule acting as a biased agonist of the glucagon-like peptide-1 receptor, which is a validated drug target for managing type-2 diabetes mellitus and obesity.

Stocks, Investors, Performance